Payment Breakdown by Category
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $201.64 | 6 | 89.3% |
| Education | $24.21 | 2 | 10.7% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Tactile Systems Technology Inc | $72.90 | 2 | $0 (2022) |
| Incyte Corporation | $64.75 | 1 | $0 (2017) |
| Novartis Pharmaceuticals Corporation | $33.25 | 1 | $0 (2024) |
| Seagen Inc. | $15.54 | 1 | $0 (2023) |
| PUMA BIOTECHNOLOGY, INC. | $15.20 | 1 | $0 (2021) |
| Seattle Genetics, Inc. | $12.29 | 1 | $0 (2018) |
| Gilead Sciences, Inc. | $11.92 | 1 | $0 (2021) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $33.25 | 1 | Novartis Pharmaceuticals Corporation ($33.25) |
| 2023 | $15.54 | 1 | Seagen Inc. ($15.54) |
| 2022 | $72.90 | 2 | Tactile Systems Technology Inc ($72.90) |
| 2021 | $27.12 | 2 | PUMA BIOTECHNOLOGY, INC. ($15.20) |
| 2018 | $12.29 | 1 | Seattle Genetics, Inc. ($12.29) |
| 2017 | $64.75 | 1 | Incyte Corporation ($64.75) |
All Payment Transactions
8 individual payment records from CMS Open Payments
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 03/21/2024 | Novartis Pharmaceuticals Corporation | LUTATHERA (Drug), PLUVICTO | Food and Beverage | In-kind items and services | $33.25 | General |
| Category: Oncology | ||||||
| 05/25/2023 | Seagen Inc. | TUKYSA (Drug) | Food and Beverage | In-kind items and services | $15.54 | General |
| Category: Oncology | ||||||
| 12/08/2022 | Tactile Systems Technology Inc | Flexitouch Plus (Device), entre | Food and Beverage | In-kind items and services | $56.17 | General |
| Category: PNEUMATIC COMPRESSOR | ||||||
| 11/10/2022 | Tactile Systems Technology Inc | Flexitouch Plus (Device), entre | Food and Beverage | In-kind items and services | $16.73 | General |
| Category: PNEUMATIC COMPRESSOR | ||||||
| 06/01/2021 | Gilead Sciences, Inc. | — | Education | In-kind items and services | $11.92 | General |
| 05/21/2021 | PUMA BIOTECHNOLOGY, INC. | NERLYNX (Drug) | Food and Beverage | In-kind items and services | $15.20 | General |
| Category: ONCOLOGY | ||||||
| 04/11/2018 | Seattle Genetics, Inc. | ADCETRIS (Biological) | Education | In-kind items and services | $12.29 | General |
| Category: Oncology | ||||||
| 05/17/2017 | Incyte Corporation | — | Food and Beverage | Cash or cash equivalent | $64.75 | General |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 80 | 5,406 | 147,469 | $11.0M | $1.8M |
| 2022 | 73 | 4,941 | 158,088 | $11.6M | $2.3M |
| 2021 | 80 | 5,334 | 170,343 | $13.0M | $3.0M |
| 2020 | 83 | 5,590 | 195,738 | $11.6M | $2.5M |
All Medicare Procedures & Services
316 procedure records from CMS Medicare Utilization — Page 1 of 13
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| J9271 | Injection, pembrolizumab, 1 mg | Office | 2023 | 33 | 19,000 | $2.8M | $822,727 | 29.5% |
| J9144 | Injection, daratumumab, 10 mg and hyaluronidase-fihj | Office | 2023 | 15 | 5,940 | $809,460 | $226,177 | 27.9% |
| J9264 | Injection, paclitaxel protein-bound particles, 1 mg | Office | 2023 | 11 | 11,210 | $482,030 | $109,882 | 22.8% |
| J2506 | Injection, pegfilgrastim, excludes biosimilar, 0.5 mg | Office | 2023 | 33 | 828 | $1.2M | $69,616 | 5.8% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 337 | 753 | $202,798 | $69,573 | 34.3% |
| 96413 | Administration of chemotherapy into vein, 1 hour or less | Office | 2023 | 185 | 592 | $494,006 | $58,506 | 11.8% |
| Q5119 | Injection, rituximab-pvvr, biosimilar, (ruxience), 10 mg | Office | 2023 | 15 | 2,210 | $428,740 | $51,183 | 11.9% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 486 | 773 | $140,184 | $46,572 | 33.2% |
| J1568 | Injection, immune globulin, (octagam), intravenous, non-lyophilized (e.g., liquid), 500 mg | Office | 2023 | 11 | 1,218 | $305,236 | $40,921 | 13.4% |
| J1439 | Injection, ferric carboxymaltose, 1 mg | Office | 2023 | 27 | 30,750 | $153,750 | $26,813 | 17.4% |
| J0897 | Injection, denosumab, 1 mg | Office | 2023 | 11 | 1,320 | $91,500 | $23,970 | 26.2% |
| J0185 | Injection, aprepitant, 1 mg | Office | 2023 | 56 | 13,780 | $124,020 | $19,008 | 15.3% |
| M0010 | Enhancing oncology model (eom) monthly enhanced oncology services (meos) payment for eom enhanced services | Office | 2023 | 47 | 219 | $15,330 | $15,082 | 98.4% |
| J9041 | Injection, bortezomib, 0.1 mg | Office | 2023 | 14 | 3,010 | $373,240 | $12,695 | 3.4% |
| 85025 | Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | Office | 2023 | 504 | 1,653 | $57,855 | $12,529 | 21.7% |
| 96417 | Administration of additional new drug or substance into vein, 1 hour or less | Office | 2023 | 75 | 237 | $96,487 | $11,787 | 12.2% |
| J0881 | Injection, darbepoetin alfa, 1 microgram (non-esrd use) | Office | 2023 | 13 | 5,030 | $105,630 | $11,707 | 11.1% |
| 96375 | Injection of additional new drug or substance into vein | Office | 2023 | 164 | 941 | $98,805 | $11,175 | 11.3% |
| 80053 | Blood test, comprehensive group of blood chemicals | Office | 2023 | 442 | 1,053 | $65,286 | $10,857 | 16.6% |
| 96365 | Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | Office | 2023 | 138 | 218 | $66,272 | $9,971 | 15.0% |
| J9217 | Leuprolide acetate (for depot suspension), 7.5 mg | Office | 2023 | 16 | 74 | $291,412 | $9,830 | 3.4% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 66 | 74 | $26,883 | $9,181 | 34.1% |
| J9070 | Cyclophosphamide, 100 mg | Office | 2023 | 23 | 572 | $155,069 | $9,165 | 5.9% |
| J9395 | Injection, fulvestrant, 25 mg | Office | 2023 | 14 | 1,040 | $272,480 | $8,240 | 3.0% |
| 96401 | Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle | Office | 2023 | 31 | 142 | $35,381 | $7,937 | 22.4% |
About Dr. Suzan Merten, M.D
Dr. Suzan Merten, M.D is a Hematology & Oncology healthcare provider based in Roanoke, Virginia. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 02/28/2006. The National Provider Identifier (NPI) number assigned to this provider is 1669448692.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Suzan Merten, M.D has received a total of $225.85 in payments from pharmaceutical and medical device companies, with $33.25 received in 2024. These payments were reported across 8 transactions from 7 companies. The most common payment nature is "Food and Beverage" ($201.64).
As a Medicare-enrolled provider, Merten has provided services to 21,271 Medicare beneficiaries, totaling 671,638 services with total Medicare billing of $9.6M. Data is available for 4 years (2020–2023), covering 316 distinct procedure/service records.
Practice Information
- Specialty Hematology & Oncology
- Location Roanoke, VA
- Active Since 02/28/2006
- Last Updated 11/02/2007
- Taxonomy Code 207RH0003X
- Entity Type Individual
- NPI Number 1669448692
Products in Payments
- Flexitouch Plus (Device) $72.90
- LUTATHERA (Drug) $33.25
- TUKYSA (Drug) $15.54
- NERLYNX (Drug) $15.20
- ADCETRIS (Biological) $12.29
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Hematology & Oncology Doctors in Roanoke
Amanda Gillespie-Twardy, M.d, M.D
Hematology & Oncology — Payments: $15,362
Mark Kochenderfer, Md, MD
Hematology & Oncology — Payments: $12,819
Dr. Padmaja Mallidi, M.d, M.D
Hematology & Oncology — Payments: $1,580
Dr. Harry Mccoy, M.d, M.D
Hematology & Oncology — Payments: $544.52
Mrs. Kirsten Hinson, Fnp-C, FNP-C
Hematology & Oncology — Payments: $421.40
Joshua Morales, Md, MD
Hematology & Oncology — Payments: $412.41